Q&A: Getting candid with Noah Phillips

Federal Trade Commission member Noah Phillips spoke with FTCWatch reporters June 7 on a balcony outside his office overlooking 600 Pennsylvania Avenue, NW. Inside his office, a picture hangs on the wall of conservatives’ bête noire, Louis...

Neill Averitt

What changes are coming with the merger guidelines?

The antitrust agencies are busy considering possible revisions to the horizontal merger guidelines. Recent speeches and writings by some key players give us hints of what the final product might look like.

Current Issue: 796

FTC in the driver’s seat on vehicle-industry regulation

The Federal Trade Commission has been given enhanced powers to regulate the $620 billion car-sales and finance industry under the Dodd-Frank Wall Street Reform and Consumer Protection Act---and it...

Is innovation an antitrust innovation?

Are the effects on innovation becoming an important new criterion in government antitrust deliberations?

FTC’s Rosch predicts trouble with ACOs

Health-care providers who want to participate in the Medicare Shared Savings Program by joining together to form Accountable Care Organizations will need to police themselves carefully to avoid...

FTC sides with dental hygienists in Maine

The FTC staff told the Maine Board of Dental Examiners that its proposed rules on dental hygienists could restrict a pilot project designed to expand access to dental services in areas where no...

Second look at Lundbeck

An eight-day bench hearing held in Minneapolis, Minn., in December 2009, could have far-reaching legal implications for antitrust law, particularly regarding future pharmaceutical cases. It could...

Gilead Science vies for purchase of Pharmasset

Biotechnology firm Gilead Sciences, the leading maker of HIV drugs, has announced its plans to acquire a rival firm, Pharmasset, for $11 billion.




Access all archived issues back to 1994